紫杉醇联合奥沙利铂和卡培他滨治疗晚期胃癌的临床观察

目的　评价紫杉醇联合奥沙利铂和卡培他滨（ＰＯＸ方案）治疗晚期胃癌的疗效和不良反应。方法　２１例晚期胃癌患者均采用ＰＯＸ方案治疗：紫杉醇８５ｍｇ／ｍ^２，第１、８天，静脉滴注；奥沙利铂１３０ｍｇ／ｍ２，第１天，静脉滴注；卡培他滨１０００ｍｇ／ｍ^２分２次口服，第１～１４天，２１天为１周期。２周期评价疗效。结果　全组２１例均可评价疗效，其中ＰＲ１３例，ＳＤ６例，ＰＤ２例，客观有效率为６１.９％；中位肿瘤进展时间为５.７个月，中位总生存期为１１个月。不良反应主要为骨髓抑制、恶心呕吐和外周神经毒性。结论　紫杉醇联合奥沙利铂和卡培他滨治疗晚期胃癌疗效较好，不良反应可耐受，值得临床进一步研究。

Clinical observation of advanced gastric cancer treated with paclitaxel plus oxaliplatin and capecitabine

Objective To investigate the efficacy and toxicity of paclitaxel plus oxaliplatin and capecitabine （ POX regimen） chemotherapy in treatment of advanced gastric cancer （AGC）. Methods Twenty-one patients with advanced gastric cancer were treated with paclitaxel 85mg/m^2 intravenously on day 1 and day 8, oxaliplatin 130mg/m^2 intravenously on day 1, and capecitabine 1000mg/m^2 orally twice a day from day 1 to day 14. The chemotherapy regimen was repeated once every 3 weeks, and all patients received at least 2 cycles of chemotherapy. Results All 21 cases were available to evaluate effect. Among them, There was no complete response （CR）, 13 partial response （PR）, 6 stable disease （SD） and 2 progress disease （PD）. The overall response rate （RR） was 61.9%, time to progression was 5.7 months and median survival time was 11 months. The main toxicities were myelosuppression, nausea, vomiting, and neutropenia. Conclusion The study proves that paclitaxel plus oxaliplatin and capecitabine regimen is an effective and well tolerated treatment for AGC, which is worthy of further clinical research.